This guideline covers identifying and managing depression in adults aged 18 years and older, in primary and secondary care. It aims to improve care for people with depression by promoting improved recognition and treatment.
MHRA advice on valproate: In February 2020, we amended a recommendation in the section on combining and augmenting medications in line with the MHRA guidance on valproate use by women and girls. The MHRA states that valproate must not be used in women and girls of childbearing potential (including young girls who are likely to need treatment into their childbearing years), unless other options are unsuitable and the pregnancy prevention programme is in place. This is because of the risk of malformations and developmental abnormalities in the baby. See update information for details.
This guideline includes recommendations on:
This guideline updates and replaces NICE guideline CG23 (December 2004).